Enhancing Communication Between Sponsor And Reviewer: A Closer Look At China's Drug Approval Process
This article was originally published in PharmAsia News
Although SFDA knows there are difficulties in registering new products in China, enacting real change may be a slow process.
You may also be interested in...
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7
SHANGHAI - The pharmaceutical industry should take advantage of China's desire to become a destination of choice for global clinical trials to encourage streamlining of regulatory requirements and expansion of clinical study sites, according to an April 1 panel discussion during the China 2008 Pharmaceutical R&D Summit in Shanghai
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.